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Development of novel methods to minimize the impact of sequencing errors in the
next-generation sequencing data analysis
Publication No._____________
Xiaofeng Zheng, M.S.
Supervisory Professor: Shoudan Liang, Ph.D

Next-generation sequencing (NGS) technology has become a prominent tool in
biological and biomedical research. However, NGS data analysis, such as de novo
assembly, mapping and variants detection is far from maturity, and the high sequencing
error-rate is one of the major problems. .
To minimize the impact of sequencing errors, we developed a highly robust and
efficient method, MTM, to correct the errors in NGS reads. We demonstrated the
effectiveness of MTM on both single-cell data with highly non-uniform coverage and
normal data with uniformly high coverage, reflecting that MTM’s performance does not
rely on the coverage of the sequencing reads. MTM was also compared with Hammer
and Quake, the best methods for correcting non-uniform and uniform data respectively.
For non-uniform data, MTM outperformed both Hammer and Quake. For uniform data,
MTM showed better performance than Quake and comparable results to Hammer. By
making better error correction with MTM, the quality of downstream analysis, such as
mapping and SNP detection, was improved.
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SNP calling is a major application of NGS technologies. However, the existence
of sequencing errors complicates this process, especially for the low coverage (<5×)
data. Since many NGS studies are now based on data with low to medium coverage
(<20×), on which most existing SNP calling methods perform poorly, we developed a
Bayesian-based approach for calling SNPs that is robust to the sequencing depth. We
successfully applied this approach to identify the SNPs in prostate cancer cell line PC-3
and colon cancer cell lines RKO and SW48, whose mutation status are unknown. Our
method outperforms the existing methods - Varscan and DNAnexus - by identifying
more SNPs while maintaining higher dbSNP rates, especially for the low coverage PC-3
data. In summary, we identified 107 potential causal genes for PC-3. For RKO and
SW48 cell lines, 701 and 652 potential causal genes were identified respectively, and
297 genes are in common. With the ability of piggybacking on the ChIP-Seq, RNA-Seq
and other data with low or uneven coverage, this approach is expected to have a wide
range of applications.
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CHAPTER ONE

Introduction & Aims

1

Next-generation sequencing (NGS), as one of the most influential breakthroughs
in the biological sciences in the past decades, revolutionized the genomic research. The
introduction of NGS technology has changed the way to acquire genetic information
from various species to an unprecedented level on speed and cost.

1. Advance in DNA sequencing technologies
DNA sequencing is the process to examine the nucleotide order of a DNA
sequence. Deciphering DNA sequence plays an essential role in biological researches.
Since early 1990s, the capillary electrophoresis (CE) - base Sanger sequencing [1-3] has
dominated the industry of genome analysis for almost two decades and led to many
monumental accomplishments, including finishing a "rough draft" of human genome [4].
However, Sanger sequencing is hampered by its inherent limitation on throughput,
scalability and speed. Thus, an entirely new technology is required to overcome such
limitations. Sanger sequencing was considered as the first-generation sequencing, and
the new sequencing technologies are referred as next-generation sequencing. It has been
seven years since the advent of NGS, and the increase of its data output has outpaced
Moore's law, at a rate of more than doubling each year. In 2007, a single sequencing run
produced the maximal 1 GB data, and in 2011, 1TB data could be produced in a single
sequencing run, which is ~1000 times of increase. Meanwhile, the dropping speed of
the sequencing cost is faster than Moore’s law. These days, more than five human
genomes can be sequenced in a single run with the cost of less than $5,000, and analyze
the data within one week. In comparison, the Sanger sequencing would take ~10 years
to produce these data and additional 3 years to finish the analysis, which costs nearly 3
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billion US dollars. Figure 1.1 shows the cost change of sequencing a human-sized
genome.

2. Platforms of NGS
NGS is the technology that can sequence millions of DNA sequences in parallel.
It includes two types of techniques, which are distinguished with the names of "secondgeneration" and "third-generation". Second-generation sequencing works by
amplifying the DNA templates immobilized on a solid matrix and sequencing them
cyclically, while the third-generation sequencing employ single molecule PCR-free and
cycle-free protocols. There are three second-generation platforms: 454 sequencing
(Roche Applied Science), Solexa sequencing (Illumina Genome Analyzer), and SOLiD
sequencing (Applied Biosystems). The third-generation sequencing such as Pacific
Biosciences is still not mature and may take may take a few years to rival the secondgeneration platforms and become the mainstream of the market. Therefore, we will only
discuss the second-generation platforms here. The comparison of these three secondgeneration sequencing platforms is in Table 1.1.

2.1.

Roche 454 system

Roche 454 technology is the first NGS technology that was released to the
market in 2005. Initially in 2005, the read length of 454 was 100-150 bp, and the output
per run is 20Mb. In 2008, the upgraded 454 GS FLX system was able to produce 700bp
long reads, the accuracy of which is 99.9% after filtering. On average, 0.7 G data was
3

Figure 1.1 Typical cost of sequencing a human-sized genome, on a logarithmic
scale. Note that the drastic trend faster than Moore's law beginning in January 2008 as
NGS was invented [6].

4

Table 1.1. Comparison of sequencing platforms [7]. (a) Advantage and mechanism of
sequencers. (b) Components and cost of sequencers. (c) Application of sequencers.
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output per run within 24 hours. In late 2009, the output of 454 system had upgraded to
14G per run. The advantages of 454 were its longer read length and faster speed (10
hours from starting to completion). However, the high cost of reagents (about $12.56
per million bases) became a big shortcoming of 454 system. Also, for the poly-bases
longer than 6bp, the error rate was relatively high. The comparison of 454 with HiSeq
from Illumina and SOLiD are in Table 1.1.

2.2.

Illumina GA/HiSeq system

Genome Analyzer (GA) was released by Solexa in 2006, and then purchased by
Illumina company in 2007. At first, the output of Solexa GA was 1G/run, and then
increased to 20G/run in August, 2009, and 30G/run and 50G/run respectively in
October and December in the same year. The latest release, GAIIx series, can have
85G/run. In 2010, Illumina adopted the same sequencing strategy with GA to get HiSeq
2000 launched. The output of HiSeq 2000 was 200G/run initially and improved to
600G/run recently and finished in 8 days. In the short run, it is expected to reach 1T/run,
and the cost of sequencing a personal genome would drop below 1K US dollars. The
average error rate could be below 2% after filtering. As the cheapest platform, HiSeq
2000 is able to sequence one million bases with only$0.02.

2.3.

AB SOLiD system

In 2006, after the Solexa was released, SOLiD (Sequencing by Oligo Ligation
Detection) entered the market in 2007. Initially, the read length of SOLiD produced 3G
35-bp-long reads per run. By means of the dinucleotide sequencing method, the
6

accuracy of SOLiD could reach 99.85% after filtering. In late 2010, three years later,
with the release of SOLiD 5500xl sequencing system,30G reads with of the length of 85
bp and accuracy of 99.99% were produced in a single run in 7 days. The current cost
using SOLiD 5500xl is about $0.04/million bases. But the limitation on de novo
sequencing and large genome sequencing is still its major shortcoming.

3. Mechanism for various platforms of NGS
Although the sequencing biochemistry and the array generation are quite diverse
for different platforms, their workflows are similar in concept (Figure 1.2). Secondgeneration sequencing follows two principles: DNA templates immobilized and
separated on a solid matrix are amplified with DNA polymerase; the replicated DNA
are sequenced cyclically. For the library preparation, the DNA sequences are randomly
fragmented and ligated to common adaptor sequences in vitro. PCR primers
complementary to the adaptor sequences are used to amplify the library immobilized on
the support matrix for amplification purpose. Emulsion PCR (emPCR) was employed
by both SOLiD and Roche 454 system to clone DNA templates linked to beads [8]. The
concentration of beads and template that are added to a water and oil emulsion are
controlled carefully to guarantee each emulsion droplet only contains one bead and one
DNA template. We call the amplified beads sequencing features. After emPCR, the
sequencing features are randomly deposited to pico-wells [11, 12]. Differently from 454
and SOLiD, Solexa employs bridge PCR to generate clonally amplified DNA clusters
[13].

7

Figure 1.2. Work flow of second-generation sequencing. In shotgun sequencing with
cyclic-array methods, common adaptors are ligated to fragmented genomic DNA, which
is then subjected to one of several protocols that results in an array of millions of
spatially immobilized PCR colonies or "polonies" [9]. Each polony consists of many
copies of a single shotgun library fragment. As all polonies are tethered to a planar array,
a single microliter-scale reagent volume (e.g., for primer hybridization and then for
enzymatic extension reactions) can be applied to manipulate all array features in parallel.
Similarly, imaging-based detection of fluorescent labels incorporated with each
extension can be used to acquire sequencing data on all features in parallel. Successive
iterations of enzymatic interrogation and imaging are used to build up a contiguous
sequencing read for each array feature [10].
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Each NGS platform uses a unique sequencing chemistries and methods for
signal detection. 454 employs pyrosequencing, whereby the nucleotide species is
indicated by the chemiluminescent and the number of bases incorporated are correlated
to the intensity of signal. Illumina uses reversible dye terminator in each cycle to
incorporate a single base, and then image and cleave the terminator in the end. Solid
employs sequencing by ligation to measure every base twice by dinucleotide encoding.
Compared with Sanger sequencing, NGS has the following advantages: (1)
construction of a sequence library and clonal amplification all in vitro provide the basis
of parallel sequencing, which breaks the limitation of conventional sequencing. (2) The
replacement of the conventional capillary-based sequencing with array-base sequencing
greatly increases the degree of parallelism. As the size the array features are in the scale
of micrometer, the imaging process becomes more efficient. (3) The array-based design
dramatically reduced the dosage of reagent from the scale of microliters to picoliters or
femtoliters per feature drop. All these advantages result in the remarkably lower cost of
NGS.

4. Applications of NGS
4.1.

Whole genome sequencing

Whole genome sequencing is the sequencing process that determines the
complete DNA sequence of organism's genome at a single time. It includes de novo
sequencing and whole genome resequencing. De novo sequencing is the sequencing
without prior knowledge of the sequenced genome, and its purpose is to assembly a new
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genome with the sequencing reads. De novo sequencing is required for decipher the
unknown genomes. As a predominant application of NGS, whole genome resequencing
can provide complete genetic information for individual's genome or cancer genome. It
is usually used to detect genome-wide single nucleotide variants, indels, copy number
variations, and genomic rearrangements [14].

4.2.

Targeted Sequencing

Targeted sequencing is the process that only sequence the region that the
researchers are interested in. Instead of sequencing the whole genome, this method
reduces the time, cost, and providing a higher sequencing coverage. It is usually used to
discover the genetic variations by sequencing many individuals. The ability of obtaining
high coverage enables NGS to identify rare variants.
Amplicon sequencing is one of the targeted sequencing techniques that
sequences selected genome regions of hundreds of base pairs long. Amplicon library
can be prepared with commercially available kits, which allow the researchers to
prepare the customized targeted region from multiple samples within hours.
Similarly to Amplicon sequencing, target enrichment is also a technique that
selectively sequences the genes or regions that researchers are interested in. Differently
to Amplicon, target enrichment allows researchers to sequence longer DNA sequences
and larger amount of DNA from each sample. A lot of kits are available for the
researcher to prepare the library. People can also design their own probes to sequences
the regions related to their interest. Exome sequencing, also known as exome capture, is
the most popular application of target enrichment approaches. It only sequence the
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protein coding regions of the genome. Compared to whole genome sequencing, it is
cheaper, but still effective. Exons constitute about only 1% of the human genome [15],
which is ~30Mb in length, but about 85% of the disease-causing mutations are
associated with these regions [16]. The work flow of exome capture is shown in Figure
1.3.

4.3.

RNA-Seq

RNA-Seq, also known as an "Whole Transcriptome Sequencing" [17], is an
approach that sequences cDNA with NGS technologies to obtain information about the
RNA content of a sample. It has been adopted to the disease associated studies and
dubbed "a revolutionary tool for transcriptomics" [18]. With the deep coverage and
base-level resolution, RNA-Seq is primarily used to study the gene expression profiling,
including gene alleles and differently spliced transcripts [19]. Meanwhile, RNA-Seq is
often used to provide information about non-coding RNAs, post-transcriptional variants,
and gene fusions. However, the significantly different expression levels between genes
usually result in insufficient coverage to accurately call variants.
The RNA library preparation varies for different platforms of NGS [18], each of
which has several kits designed to build different types of libraries. However, the
workflows of different sequencing technologies are similar in concept. To separate the
coding RNA from non-coding RNA, poly(T) oligos are designed to covalently attached
to the 3' poly(A) tail of mRNA. Magnetic beads are used in many studies for this step
[17, 21]. The next step is to reversely transcribe the RNA to cDNA and further fragment
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Figure 1.3 Exome sequencing workflow .
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the cDNA to reach the desired length. The templates are then ready to be prepared for
the sequencing. The workflow of RNA-Seq is shown in Figure 1.4.

4.4.

ChIP-Seq

ChIP-Seq (chromatin immunoprecipitation sequencing) is used to identify the
binding sites of DNA-associated proteins. ChIP-Seq is primarily used to study how
DNA-associated proteins, such as transcription factors and histone, interact with DNA
to regulate the gene expression, which plays an essential role in deciphering biological
processes.
Some DNA sites interact directly with transcription factors or other proteins to
form DNA-protein complexes, which can be isolated by chromatin immunoprecipitation
with antibody against the protein of interest. Then the small pieces of DNA bound to the
interested protein are ligated to oligonucleotide adaptors for the following sequencing
(Figure 1.5).

5. Bioinformatics for NGS
Although the NGS technologies are developing at a rapid pace, the short read
and the sheer scale data remains a significant challenge in data analysis.

13

Figure 1.4 Workflow of RNA-Seq .
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Figure 1.5 Workflow of RNA-Seq .
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5.1.

Sequencing error and quality score

The primary data from NGS consists of raw sequencing reads and the quality
score for each base. The quality scores from different sequencing platforms cannot be
compared directly, but all of them are Phred-like scores that are related to the
sequencing error probabilities logarithmically. Different sequencing platforms generate
various types of error. For the 454 platform, the length of each homopolymer is inferred
from the observed fluorescence intensity, while the variance of the intensity for a
specific homopolymer length is large. So 454 system has high error rate in insertion and
deletion (indel) calls. For the Illumina platform, indels are rare. The major sequencing
errors come from miscall, with a typical rate of ~1%. The SOLiD platform uses
dinucleotide encoding scheme, in which each base is called twice. Thus the sequencing
error rate in SOLiD is relatively smaller. For both Illumina and SOLiD platforms, base
calling becomes less accurate towards the ends of reads. Depending on the platform, the
error rate of NGS data ranges from several per cent to tenths of per cent. Reducing the
sequencing errors is important to the assembly, alignment, variants detection and other
downstream genomic analysis.

5.2.

NGS analysis pipeline

Usually after the NGS reads are generated, the first step is either aligning the
reads to a reference genome or doing de novo assemble, which is the basis of the
analysis thereafter.
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5.2.1.

Alignment

Aligning the massive, short sequencing reads to the huge reference genome is a
computationally complicated problem. Many alignment algorithms were developed and
some the most popular ones are MAQ, BWA and bowtie. Illumina has developed their
own aligner Eland, and SOLiD also developed Bioscope for their customers. There are
some limitations to the alignment approaches. Errors often occur because of the
ambiguous bases and the sequencing errors in the short reads. Multi-mapping are
frequently observed when the reads are placed in the repetitive regions in the reference
genome [24]. Moreover, the presence of gaps and misassemblies in the imperfect
reference genome also leads to misalignment [25, 26]. Pair-end reads can resolve the
misalignment for some repetitive regions if one read in the pair is unique to the genome.

5.2.2.

De novo assembly

de novo assembly refers to aligning and merging the sequencing reads to
reconstruct the original sequenced genome. It is important as the reference genome is
lack for most species. Compared with alignment, assembly is computationally orders of
magnitude slower and more memory intensive. De novo assembly has been successfully
applied to assemble the bacterial genomes and mammalian bacterial artificial
chromosomes [27-31]. However, the application to human genome remains a
substantial challenge. The short read length usually leads to a lot of gaps, regions
without reads aligned, and the sequencing errors often cause branching, resulting in
poor assembly quality. Pair-end reads could partially resolve this problem and produce
longer contigs by filling gaps in the consensus sequence.
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5.2.3.

Variants detection

Variants detection is one of the most important applications of NGS, with the
challenge of separating the real variants from sequencing errors. Most variants detection
methods use Bayesian algorithms to estimate the probability of calling a variant at a
specific position. Variants detection has become more sophisticated and the further
steps, such as local realignment around indels, quality score recalibration, and removal
of duplicates, are usually implemented to improve the accuracy of variant calling. Once
the variants are detected, they are typically annotated to predict the functional
significance.

6. Significance and specific aims
Since the first introduction in 2005, NGS technologies have generated an
incredible impact on genomic research. They have been broadly applied to many fields
including genomic variation detection, gene expression and profiling, protein-DNA
interaction, detection of aberrant transcription, small ncRNA discovery and profiling,
genome annotation, and epigenomics. However, the development of methods for NGS
data analysis is far away behind the advances of NGS technology itself. More efficient
data analysis methods are required to establish pipeline for many applications before the
analysis becomes routine. One major obstacle of data analysis is sequencing error,
which affects the efficiency and accuracy of the analyzed results. Therefore, the purpose

18

of my study is to design data analysis methods that can minimize the effect from
sequencing errors. The two aims are described as below:
1) To design a robust and efficient error-correction method to correct the
sequencing reads before the downstream analysis. Most of the existing errorcorrection methods require high and uniform coverage, which does not fit some
sequencing applications, such as single-cell sequencing, and mRNA-Seq. Here,
we will design an error-correction method without any requirement for the
sequencing coverage.
2) To design a SNP calling method. The existence of sequencing error usually
results in low SNP-calling accuracy for low coverage data. Here we will design
a new model to accurately detect the SNPs without requirement for the
sequencing depth of the data.
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CHAPTER TWO

MTM: An Error-Correction Method for HighThroughput Sequencing Data
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1. SUMMARY
Background
NGS technologies produce massive amounts of short reads. The high
sequencing error rate has become one of the major obstacles in sequencing data
applications, such as de novo assembly and re-sequencing. Thus, error correction prior
to data analysis is a critical step for the success of downstream analysis. Several errorcorrection methods have been developed in recent years. Most of those methods work
with the assumption that sequencing reads are uniformly distributed. Although a few
methods work well on the non-uniform data, they are computationally expensive and do
not perform as well as the uniformity-specific methods on the uniform data. Therefore,
a robust and efficient error-correction method is in urgent need.
Results
We report MTM, a new method for correcting errors in the NGS reads without
the uniformity assumption. By using a mutating-testing algorithm, MTM outperforms
the pervious error-correction methods with robustness, as well as higher positive
predictive values and sensitivities. We also demonstrated the improvements of error
correction with MTM on the mapping and variant detection.
Conclusions
MTM is a robust and efficient error correction method for NGS data, which can
improve the quality of the results in the subsequent analysis. It is implemented in C++
and has been released as a software package downloadable at
https://sites.google.com/site/mtmerrorcorrection/
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2. INTRODUCTION
NGS technology developed in the last decade provides monumental increase in
speed and volume, taking biological and biomedical research to a whole new level. For
example, tumour samples from thousands of patients (TCGA) have been sequenced in
order to discover the complete set of oncogenes and tumour suppressor genes. The 1000
Genome Project is using sequencing to establish by far the most detailed catalogue
of human genetic variations [32]. Thus far, the applications are mostly confined to the
organisms whose genomes have been sequenced. A more exciting possibility is to
expand the new sequencing capacity to the study of genome biology of previously
unexplored organisms. Meanwhile, the Genome 10K Project plans to sequence and
assemble the genomes of 10,000 vertebrate species [33].
Compared to the traditional shotgun methods [34], the NGS techniques generate
a much larger set of shorter reads with higher error rates, which challenge the
downstream analysis tools. Sanger reads, typically 700-1000 bp long, were assembled
using an overlap-layout-consensus approach, which would be too slow when applied to
the NGS data. Thus, a new method has been developed using de Bruijn graph [35] that
is much faster to compute large amount of sequencing data [36]. However, methods
based on de Bruijn graph are highly sensitive to sequencing errors [37], which cause
branching in the graph and greatly increase the computational cost. Therefore correcting
sequencing errors before assembly is a build-in feature of almost all de Bruijn
assemblers. Re-sequencing is another important application of NGS technology. Reads
are aligned to the reference genome by allowing up to a fixed number of mismatches
caused by either polymorphisms or sequencing errors [38]. Therefore, some reads are
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difficult to be mapped to the reference genome due to the sequencing errors, especially
in the polymorphism-rich regions. Pre-processing the reads to eliminate sequencing
errors will improve the mapping ability. Subsequently, the sensitivity and specificity of
variant detection will be improved as well.
The general idea behind error correction methods is to align all the reads that
cover the same genome locations, and identify the erroneous base using the high
coverage of the NGS technology. As the reference genome is unknown, the reads from
the same genome location refer to the reads sharing the same subsequence of a fixed
length k, called k-mers [39]. Established error correction methods can be classified into
three types - k-spectrum based [28, 36, 40-47], suffix tree/array-based [48-50] and
multiple sequence alignment (MSA) -based methods [51, 52]. A common approach of
error correction is to use the frequency of k-mers to separate them into trusted k-mers
and untrusted k-mers. k-mers with low frequency usually represent sequencing errors,
while k-mers with high frequency are likely to occur in the genome. When the
sequencing coverage is high and uniform, the distributions of trusted k-mers and
untrusted k-mers are separated. By choosing a right threshold, they can be separated
very well [28, 36, 43, 46, 47]. However, these methods do not work well when the data
does not cover the genome uniformly. For example, data from transcriptome sequencing
(RNA-Seq) and single-cell sequencing, the coverage of which are dramatically uneven.
Also, when the DNA is from environmental samples and cannot be cloned, the amount
of starting materials is small. Using above methods to pre-process these data is not
effective and results in loss of real reads. Another popular approach is based on
Hamming graph. k-mers within a small Hamming distance are grouped together, and the
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k-mers with low frequency are corrected to the high-frequency k-mer [44, 48-50, 53, 54].
Although some of these methods work well for non-uniform data, but they can be
computationally expensive and do not perform as well as the methods based on k-mers
frequency on uniform data.
In this paper, we present a new method MTM to correct sequencing errors,
without the assumption on the uniformity of the data. MTM is similar in spirit to the
Hammer graph methods. It assumes that the k-mer population is consisted of high
frequency error-free k-mers and low frequency erroneous k-mers, and that an erroneous
k-mers can be linked to an error-free k-mer by a small number of point mutations. It
further assumes that the ratio of the frequencies of the linked k-mers is consistent to the
sequencing error rate. MTM outperforms the previous non-assumption methods on both
uniform and non-uniform data, and achieved similar performance to uniformity-specific
methods on uniform data. MTM is efficient on dealing with large datasets or data with
high error rates without the limitation on memory. Moreover, MTM allows users to
choose a large range of k-mer length, providing more flexibility for the downstream
analysis. Finally, we explored the impact of error correction with MTM on mapping
ability and variant detection. After error correction, we were able to map more reads to
the reference genome, and identify more variants while remaining the same precision.

3. MATIRIALS & METHODS
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3.1.

Data

To test the effectiveness of MTM on both uniform and non-uniform datasets, we
used two data sets: 1) Single-cell data with highly non-uniform coverage [55]. The
reads were amplified from a single-cell of E.coli K12 MG1655 and sequenced by the
Illumina GAII pipeline (lane 1). The 100 bp long reads with ~600× sequencing depth
result in 94 blackout regions and totally 116 kbp with 0 or 1 coverage. 2) Normal multicell data with uniform coverage (ERX002508). The data were also generated from
E.coli K-12 MG1655 and sequenced by the Illumina GAII pipeline with the same
coverage and read length.
Since the sequencing accuracy is low at the beginning and end of a read, prior to
working with the datasets, we trimmed the reads by only keeping the longest region of a
read that are longer than k (size of oligonucleotide) and do not contain ambiguous bases
or bases with quality score lower than QUAL_LOW. In this study, we let QUAL_LOW
equal 3.

3.2.

Statistical model
Two k-mers S1 and S2 with multiplicities

and

(

) have one

nucleotide difference in the sequences. Then S2 may either be sequenced from S1 with
one sequencing error or be a true repeat of S1 .To distinguish the sequencing error from
repeat, we tested if the percentage of S2 is consistent with the average sequencing error
rate. Define q as the average sequencing error rate and p as the percentage of k-mer S2.
Then
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distribution. By defining a significance level α, null
, where

. The rejection of null

hypothesis indicates that k-mer S2 is not the erroneous form of S1.

3.3.

Algorithm

MTM detects and corrects the sequencing errors by converting the reads to kmers and distinguishing trusted k-mers from erroneous k-mers, then using the trusted kmers to correct the original reads. Because sequencing error is small, the error free
sequences should occur more frequently than the sequences with errors. Thus, k-mers
with higher multiplicities are more trustable. MTM mutates each k-mer and searches for
its close k-mers with lower multiplicities. If a match is found, the above statistical
model is applied to determine if the matched k-mer is likely to be an erroneous form of
the original k-mer. MTM consists of the following steps:
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1) Counting k-mers: the first step of MTM is cutting the trimmed reads to k-mers
and counting the occurrences of all k-mers. A read with length L produces
k-mers.
2) Sorting k-mers: k-mers are sorted by their multiplicities from high to low.
3) Mutating and testing: Starting from the k-mer with highest multiplicity, we
work on all the k-mers in the order sorted in step 2. For each k-mer So, we
mutate one nucleotide at a time to generate a new k-mer Sm with only one
substitutional difference to the original k-mer So. A k-mer can be mutated to
new k-mers as shown in Figure 2.1(a). Then we search each new k-mer Sm in
the k-mer list with multiplicities lower than So. Once a match is found, the above
statistical model is applied to test if Sm is the result of erroneous sequencing of
Sm. If the testing result shows that Sm is erroneous, Sm will be corrected to So at
the end of this step. Meanwhile, a table is generated to record erroneous k-mers
and their corresponding corrected k-mers. Since the mutation and correction
processes are accumulative, correction could happen between two k-mers with
more than one bases difference, such as the k-mers Sa and Sc in Figure 2.1(b).
Moreover, although error free k-mers occur more frequently than erroneous kmers, high multiplicity does not guarantee that a k-mer is trustable. It is because
the sequencing coverage are often uneven, which is especially true when
amplifying from a small amount of starting materials and in RNA-Seq. Even
when de novo sequencing is performed at optimal condition, the coverage often
distributes in a wide range. A non-negligible portion of the genome have high
coverage. Therefore, a high multiplicity k-mer can be the result of sequencing
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error from a k-mer with even higher multiplicity, just like Sb in Figure 2.1(b),
which is erroneous form of Sa.
4) Correcting sequencing reads: Using the correct k-mers list and the correction
table mentioned in step 3, we map the correct k-mers back to the original reads.
If no correct k-mer is mapped to a position, the original base in the read is kept.
Otherwise, the consensus nucleotide is the base in the final correct sequence of
the read (Figure 2.2).

3.4.

Parameters

MTM has three parameters: 1) α, significance level of likelihood ratio test for
determining if the mutated k-mer is trustable. Setting α too large may reduce the power
of correction, remaining a lot of erroneous k-mers after correction. Whereas setting α
too small may reduce the sensitivity, thus losing some true k-mers. We optimized α as
0.1% in our method (Figure 2.3). 2) k, the length of oligonucleotide MTM works on.
Like the trades-offs with k-mer size in genome assembly, too small of a k results in a
high probability that one k-mer in the genome would be similar to another k-mer in the
genome with only one nucleotide substitution, making the situation more complicated.
Too large of a k results in low k-mer coverage and reduces the accuracy of algorithm.
We designed two versions of codes for MTM – binary version and string version.
Binary version is faster than the string version, while it has a limitation for k (

).

3) mulcutoff, the threshold of multiplicity below which the k-mers will be removed.
Varying the value of mulcutoff results in a trade-off between sensitivity and specificity.
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Figure 2.1. Illustration of k-mer mutation and accumulative correction. (a) One kmer is mutated to 3k new k-mers with one nucleotide substitution. (b) This is an
example of accumulative correction. We mutate k-mer Sa by one nucleotide and find a
match Sb. The statistical test shows Sb is the result of sequencing error from Sa. So Sb is
corrected to Sa. Similarly, then we do mutation to Sb and find out that Sc can be
corrected to Sb. Therefore, Sa is the original correct form of Sc.
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Figure 2.2. Correction of original sequencing reads with trusted k-mers. This is an
example indicating the way that the sequencing reads are corrected based on the correct
k-mers. We mapped k-mers back to the original read, and correct the sequence of the
original read to the consensus of k-mers. The region with no k-mers mapped is saved.
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Figure 2.3. Sensitivity ~ PPV plots of MTM with different  values. We measured
the sensitivities and PPVs by choosing different  values.  value is labeled next to the
curves. When  changes from 0.1% to 0.01%, the sensitivities decrease. So on balance,
0.1% is the recommended value for .
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4. RESULTS
MTM corrects errors in the sequencing reads. To achieve this goal, MTM
converts the reads to k-mers and separates the error-free k-mers from the erroneous kmers, and then replaces the k-mers from the original reads with error-free k-mers.
Therefore, finding out the error-free k-mers is the critical step of MTM. To assess
MTM's ability, following Medvedev et al.[45], we measured the data's sensitivity and
positive predictive value (PPV) with respect to the reference E.coli genome. Sensitivity
is measured by the percentage of E.coli genome's k-mers that are present in the dataset.
PPV is the percentage of data's k-mers that are present in the E.coli genome.
To test the performance of MTM on different k values, two different values of k
(k = 31 and k = 55) were used to run MTM for each dataset. We ran the binary version
program for k = 31 and ran the string version program for k = 55. To increase the
quality of the reads, we trimmed the data before running MTM, and about 85% - 91%
of the data were preserved. The trimming step did not affect the high sensitivities of the
data, which are 99.98% (k = 55) and 99.99% (k = 31) for the normal data, and 97.04%
(k = 55) and 97.72% (k = 31) for the single-cell data. Error correction by MTM
dramatically reduced the percentage of erroneous k-mers, especially when the mulcutoff
is larger than one (Figure 2.4).

4.1.

Comparison to other methods

Quake is a program that is superior in detecting as well as correcting sequencing
errors in the data with high and uniform coverage [43]. Quake works by weighting the
k-mer multiplicities with quality values and then modelling the histogram of weighted
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Figure 2.4. Error correction by MTM removed the majority of the erroneous kmers. We measured the PPV of normal and single-cell data by varying mulcutoff in the
MTM. After the error correction by MTM, the percentage of erroneous k-mers
dramatically decreased, especially when k ≥ 2. The vertical axis is 1-PPV, which is the
percentage of data's k-mers that are not present in the E.coli genome. Black color
represents the results before the correction, and the grey color represents the results
after correction.
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multiplicities as at mixture of two distributions to choose an appropriate cutoff between
error-free k-mers and erroneous k-mers. Quake is not able to find the cutoff for the
single-cell data, so we manually tried different values as the cutoff and compared the
results with MTM (Figure 2.5). MTM works better than Quake because its curve is
closer to the top right corner, which indicates higher sensitivity and PPV. Based on the
plots, we choose 4 as the cutoff for MTM, because by using the cutoff of 4 MTM is able
to obtain high PPV with a negligible decrease of sensitivity. Accordingly, the cutoff of
Quake is set to 3. The number of the comparison results is showed in Table 2.1. MTM
outperformed Quake for single-cell data with both higher PPV and sensitivity, and
achieve comparable performance for normal data. When the cutoff is set to 4 for the
normal data, MTM get higher sensitivity and lower PPV than Quake. When the cutoff is
increased to 9, MTM win out with higher PPV and the same sensitivity.
Another method called Hammer was recently developed, which is popular for its
good performance on correcting non-uniformly distributed data [45]. Based on a
combination of Hamming graph and a probabilistic model, Hammer identifies the
clusters for similar k-mers and generates a consensus k-mer as the error-free k-mer for
each cluster. We also compared MTM with Hammer, and the results showed that MTM
improved Hammer on both single-cell data and normal data. Figure 2.5 shows that
MTM gets higher PPV and sensitivities at various cutoff points for single-cell data. The
number of the comparison results is shown in Table 2.1, in which the singletonCutoff of
Hammer is set to 3 according to the plots. With k=55, MTM retained ~16K more true kmers, while reduced the erroneous k-mers by ~258K for single-cell data. Similar results
are obtained with k=31.
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(a) k = 55
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(b) k = 31

Figure 2.5 Sensitivity ~ PPV plots with different error correction tools.
For single-cell data, we plotted the sensitivity and PPV with different error correction
tools by varying the cutoff values. MTM performs better than Quake and Hammer
because its curve is closer to the upper right corner, where the sensitivity and PPV are
higher. Cutoff values were labelled next to the curves with the same color as the curve.
For MTM, the cutoff is mulcutoff, k-mers with the multiplicity below which are
discarded. For Hammer and Quake, the cutoff is weighted multiplicity. "uc" represents
"uncorrected", which is the value before correction.
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Table 2.1 Comparison of MTM results with other tools. MTM outperforms
Hammer for both single-cell data and normal data. MTM also shows better performance
than Quake for single-cell data, and comparable results for normal data. The cutoff for
MTM is the value of parameter mulcutoff, k-mers with the multiplicity below which
were discarded. The cutoff for Hammer is the value of parameter singletonCutoff in
Hammer, which is the threshold for the weighted multiplicity. For Quake, the cutoff is
also based on the weighted multiplicity, and it is calculated automatically by the
program for normal data.

(a) Comparison results with k = 55.

Single-cell

normal

distinct k-mers correct k-mers

PPV (%)

sensitivity(%)

Before correction

9,602,1803

4,430,156

4.61

97.04

MTM (cutoff = 4)

4,638,400

4,268,971

92.04

93.51

Hammer (cutoff = 3)

4,896,130

4,252,619

86.86

93.15

Quake (cutoff = 3)

4,703,965

4,178,234

88.82

91.52

Before correction

81,042,139

4,564,457

5.63

99.98

MTM (cutoff = 4)

4,801,122

4,563,700

95.05

99.96

Hammer (cutoff = 3)

4,857,315

4,562,884

93.94

99.94

Quake

4,725,473

4,562,648

96.55

99.94

MTM (cutoff = 9)

4,719,529

4,562,509

96.67

99.94
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(b) Comparison results with k = 31.

Single-cell

normal

distinct k-mers correct k-mers

PPV (%)

sensitivity(%)

Before correction

90,598,084

4,450,268

4.91

97.72

MTM (cutoff = 4)

4,903,206

4,359,514

88.91

95.72

Hammer (cutoff = 3)

5,247,985

4,339,490

82.69

95.28

Quake (cutoff = 3)

5,792,076

4,360,114

75.28

95.74

Before correction

81,128,182

4,553,932

5.61

99.99

MTM (cutoff = 4)

4,755,026

4,553,849

95.77

99.99

Hammer (cutoff = 3)

4,984,462

4,550,950

91.30

99.93

Quake

4,599,644

4,553,533

99.00

99.98

MTM (cutoff = 19)

4,597,788

4,553,474

99.04

99.98
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The superiority of MTM over Quake and Hammer becomes more significant
when the data quality is low. In the above analysis, we trimmed the data by setting the
QUAL_LOW to 3, which grabbed the longest region in a read that is longer than k and
does not contain ambiguous base or base with quality score lower than QUAL_LOW. In
this part, we set the QUAL_LOW to 2. In other words, we kept all the low quality bases
in the dataset. As a result, about 8% more data was preserved on average. We plotted
the sensitivities and PPVs from different methods (Figure 2.6). Compared to Figure
2.5, the distances between the MTM curve and other two curves are larger, indicating
that the improvement of MTM on Quake and Hammer is more significant.

4.2.

Parameters selection

Optimizing the parameters could lead to better performance. The first parameter
is the length of k-mer. Longer k-mers tend to have more sequencing errors and
consequently reduce the chance that they can be reached from the trusted k-mer within a
finite number of mutations. As a result, MTM is expected to work better with smaller k.
Figure 2.7 shows the results of the single-cell data with k = 55 and k = 31 separately.
The curve for k = 31 is better because it is closer to the top right corner. This figure
indicated that the algorithm prefers smaller k. However, if the k-mer is too small, there
is a greater risk for an unrelated k-mer to accidentally match to the genome. Thus, one
should balance the pros and cons to choose an appropriate k-mer length.
α is the significance level of the statistical test that is used to distinguish the
trusted k-mers from erroneous k-mers. We measured the sensitivity and PPV by varying
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Figure 2.6 Sensitivity ~ PPV plots with different tools for low quality data (k=55).
Single-cell data in this figure was trimmed with QUAL_LOW=2. Namely, the low
quality bases were not trimmed off, and only ambiguous bases were removed. With the
correction results, we plotted the PPV-sensitivity curves for MTM, Hammer and Quake.
Compared to Figure 2, the distances between MTM curve and other two curves are
much larger, indicating that the improvement of MTM on Hammer and Quake is more
significant. Cutoff values were labelled next to the curves with the same color as the
curve. For MTM, the cutoff is mulcutoff, k-mers with the multiplicity below which are
discarded. For Hammer and Quake, the cutoff is weighted multiplicity. "uc" represents
"uncorrected", which is the value before correction.
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α value (Figure 2.3). When the value of  changes from 1% to 0.1%, the PPV increases,
while the sensitivity only has a slight decrease. However, the sensitivity decreases
significantly when  changed from 0.1% to 0.01%. So considering the balance of
sensitivity and PPV, 0.1% is recommended and is used in our analysis.

4.3.

Improvement on mapping ability

Aligning the sequencing reads to the reference genome is the first step in the
application of short reads. Mapping the short reads is usually achieved by allowing a
fixed number of mismatches [38]. In other words, if the number of sequencing errors in
a read is larger than the fixed number, the read will not be mapped. Thus, by performing
error correction before mapping, the mapping ability will be improved. We mapped the
short reads to their sequencing template E.coli K12 before and after the error correction
with MTM. We used two different modes of Bowtie to do the mapping [56]. Firstly, We
mapped the reads with Bowtie's default mode (-n mode), which allows no more than 2
mismatches in the first 28 bases, and the sum of the Phred quality values at all
mismatched positions no more than 70. Then, we also did the mapping by allowing up
to 2 mismatches for the whole read using the -v mode of Bowtie. The results are
showed in Table 2.2(a). In -n mode, about 50-70K additional reads were mapped after
the error correction with MTM. And about 220-490K additional reads were mapped
after the error correction with -v mode. The results clearly indicate the benefits of error
correction on mapping, especially for the -v mode, which allows a few of mismatches in
the whole read.
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Figure 2.7 Sensitivity ~ PPV plots of MTM with different k values. We showed the
sensitivity ~ PPV plots for k=55 and k=31 by varying the value of mulcutoff.
Apparently, with k=31, MTM works slightly better. The mulcutoff values were labelled
next to the curves with the same color as the curve. "uc" represents "uncorrected",
which is the values before correction.
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Table 2.2 Mapping results comparison. We used Bowtie to map the reads in two
different modes: -n mode and -v mode. In -n mode, up to 2 mismatches were allowed in
the first 28 bases, and the sum of Phred quality of all mismatches should not exceed 70.
In -v mode, only up to 2 mismatches were allowed in the whole reads.

(a) E.coli K12 as the reference genome.
n-mode

v-mode

before

after

before

after

24.92M

24.97M

24.56M

24.78M

(93.33%)

(93.51%)

(91.98%)

(92.81%)

normal

26.72M

26.77M

26.17M

26.55M

(k=55)

(99.42%)

(99.61%)

(97.37%)

(98.79%)

lane1 (k=31)

26.64M

26.71M

26.26M

26.59M

(93.52%)

(93.76%)

(92.16%)

(93.33%)

normal

27.82M

27.89M

27.25M

27.74M

(k=31)

(99.41%)

(99.69%)

(97.37%)

(99.13%)

lane1 (k=55)
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(b) E.coli 536 as the reference genome
n-mode

v-mode

before

after

before

after

13.43M

13.64M

12.27M

12.96M

(50.31%)

(51.09%)

(45.96%)

(48.52%)

normal

13.63M

14.03M

12.70M

13.65M

(k=55)

(50.73%)

(52.21%)

(47.27%)

(50.79%)

lane1 (k=31)

14.66M

14.91M

13.43M

14.20M

(51.47%)

(52.35%)

(47.13%)

(49.83%)

normal

14.41M

14.87M

13.43M

14.52M

(k=31)

(51.48%)

(53.14%)

(48.01%)

(51.88%)

lane1 (k=55)
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In most cases, the genome being sequenced is different from the reference
genome due to polymorphisms. The coexistence of SNPs and sequencing errors results
in difficulties in mapping the reads to the reference genome, especially to the SNP-rich
regions. So eliminating sequencing errors should benefit more when the reference
genome is different from the sequenced genome. We used a related genome E.coli 536
[GenBank: NC_008253] as the reference genome to do the same mapping (Table 2.2
(b)). About 210-460K additional reads were mapped in -n mode, and about 690-1090K
additional reads were mapped in -v mode, which demonstrated that error correction by
MTM improves the mapping ability more significantly when the reference genome is
different from the sequenced genome.

4.4.

Improvement on SNPs calling

Variants detection is an important application of NGS. By correcting the
sequencing errors before identifying the variants, mismatches between the aligned reads
and reference genome can be reduced. Therefore the SNPs-clustered regions will be
able to be mapped, resulting in more SNPs to be identified. To explore the benefit of
error correction with MTM on variants detection, we used the same method that Quake
used [43]. To call SNPs, we used the data that are sequenced from E.coli K12 but
aligned to a relative genome E.coli 536 to detect SNPs with SAMtools [57]. To
calculate the recall and precision statistics of the identified SNPs, we aligned the E.coli
K12 genome and E.coli 536 genome with the dnadiff utility in MUMmer [58], and used
the numerated SNPs as the gold standard. The results are showed in Table 2.3. After
error correction with MTM, we discovered more SNPs. In both -n mode and -v
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Table 2.3 - SNP calling. We called SNPs using the mapping results from Table 2.2 (b)
with SAMtools. The SNPs were validated by comparing them with the SNPs from the
alignment of E.coli K12 genome and E.coli 536 genome. Recall is the fraction of
identified SNPs in the true SNPs. Precision is the fraction of true SNPs in the identified
SNPs.
SNPs

k=55

k=31

Recall

Precision

before

after

before

after

before

after

lane1, -n mode

68,270

68,932

0.621

0.627

0.991

0.991

lane1, -v mode

56,287

56,916

0.512

0.518

0.992

0.992

normal, -n mode

67,472

68,833

0.615

0.627

0.993

0.993

normal, -v mode

61,044

61,830

0.556

0.564

0.994

0.993

lane1, -n mode

72,622

73,372

0.659

0.666

0.989

0.989

lane1, -v mode

62,166

63,041

0.565

0.573

0.991

0.991

normal, -n mode

71,809

73,277

0.653

0.667

0.992

0.992

normal, -v mode

65,982

67,007

0.601

0.610

0.993

0.993
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mode, the recall increased, while the precision did not change, indicating that the newly
discovered SNPs are reliable.

5. DISCUSSION
The high throughput and low cost of NGS technologies produce a revolution in
genome research. However, sequencing errors mislead and complicate the analysis of
sequencing reads. Thus, preprocessing the sequencing reads to eliminate the sequencing
errors is critical for improving the quality of downstream analysis. Despite the success
of many error-correction tools, there is a lack of an efficient tool without limitations on
the reads coverage, k-mer length and memory size. Most error-correction tools rely on
the uniformity of the reads coverage [39], which is impossible for transcriptome
sequencing and single-cell sequencing. Hammer is an alternate method working without
the uniformity assumptions. MTM, the tool we present here, is also an assumption-free
method. It outperforms the previous methods with higher PPV and sensitivity.
Especially, when the quality of the data is low, MTM shows more significant
superiority.
There is no limitation on the k-mer length, which is a strength of MTM. We
found that the processing time and required memory of Hammer increases significantly
when k is small, making it not applicable in genome assembly. Also, the correction and
reconstruction steps of Quake do not support large k due to memory limitations (19mers require 32 GB). In contrast, the flexibility of k selection makes MTM easy to
satisfy various needs. For example, long k-mers have the potential to be used to
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distinguish the repetitive regions in eukaryotic genomes. We also provide a binary
option for MTM, which greatly speeds up the analysis when k is no more than 32.
Rather than correcting k-mers, MTM detects putative erroneous k-mers and
removes them. In other words, using MTM, no new k-mers is introduced and all the kmers used to reconstruct the reads come directly from the original reads. As a
consequence, the error correction by MTM is not able to increase the sensitivity of the
data. However, without creating new k-mers, MTM eliminates the risk of introducing
false positive. Error-correction methods are designed to mainly target hyplotype
genome sequencing so far, including MTM. So extending the current MTM
implementation on processing highly repetitive eukaryotic genomes is part of our future
work. This can be achieved by extending the k-mer on both ends and searching their
consensus k-mers. The surrounding sequencing should have consistent consensus kmers with the original k-mer. Furthermore, like most error-correction algorithms, MTM
only targets on substitution errors, which is the main source of errors in Illumina
sequencing platform. The emergence of new platforms, such as PacBio sequencer and
Ion Torrent that are abundant of indels, challenge MTM. So adopting insertions and
deletions in the error correction process is our next target.
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CHAPTER THREE

A New Method of Discovering Genome-Wide
SNPs from Next-Generation Sequencing Data
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1. SUMMARY

Background
The advance of NGS technology provides an unprecedentedly efficient way to
comprehensively catalogue the human genetic variants. Ideally, SNPs can be effectively
detected by counting the allele frequency. However, the high sequencing error rates
complicate the situation, especially for low coverage (< 5×) data. Recently, many NGS
studies are based on data with low to medium coverage (< 20×). The increasing demand
for sequencing more samples suggests that the low or medium coverage sequencing
may be the most common and cost-effective design. Therefore, accurate SNP calling
methods without the limitation in the sequencing coverage is important to future genetic
studies.
Results
To improve the existing methods, we developed a Bayesian-based approach for
calling SNPs without requirement for the sequencing depth. We successfully applied
this approach to identify the SNPs in prostate cancer cell line PC-3 and colon cancer
cell lines RKO and SW48, whose mutation status are unknown. Our method
outperforms the existing methods by identify more SNPs while maintaining higher
dbSNP rates, especially for the low coverage PC-3 data. Eventually, we identified 107
potential causal genes for PC-3. For RKO and SW48 cell lines, 701 and 652 potential
causal genes were identified respectively, and 297 genes are in common.
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Conclusions
The approach we report in this article is highly sensitive and specific. It is not
only able to accurately detect SNPs from deeply sequenced exome data, it is also able to
detect SNPs by piggybacking on the ChIP-Seq, RNA-Seq and some other sequencing
data with low or uneven coverage. We expect our approach to have a wide range of
applications.
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2. INTRODUCTION
Recent advances of NGS technology reveal limitless insight about the genome,
transcriptome, and epigenome of any species. The relatively low cost and incredible
throughput of NGS makes it possible to comprehensively catalogue the genetic
variation. Projects such as 1000 Genome Project [32] and The Cancer Genome Atlas
aim to establish a complete search for variations in common diseases.
SNP calling refers to the determination of the genome positions where there are
polymorphisms or at least one of the bases is different from the reference genome. The
high error rates in NGS often cause considerable uncertainty for the SNP calling results.
Especially, when the coverage is low (< 5× per site per individual on average), the SNP
calling is difficult. To reduce the uncertainty of SNP calling, one proven method is to
sequence the targeted region deeply (> 20× coverage). However, the most common and
cost-effective sequencing method is to sequence samples in medium (5-20× coverage)
or low coverage. For example, the 1000 Genome Project sequenced 176 individuals
genome-widely at about 3× coverage, because this design is more efficient to identify
rare variants, compared with the design that sequences fewer individuals deeply [59].
Therefore, it is crucial to effectively call SNPs in low coverage data, because the
inferred SNPs will influence downstream analysis.
The SNP calling methods can be classified into two types - simple cutoff
framework and probabilistic framework. In early studies, the SNP calling analysis first
filter the sequencing data, and only the high-confidence bases would be kept. The most
common way of filtering the data is to set the threshold of the quality score to Q20.
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Bases with quality scores smaller than the threshold are ignored. Then the number of
times that each allele is observed will be counted, and the allele with largest count but
different from reference genome will be called as SNP. This type of method works well
when the sequencing depth is high. Some commercially available softwares such as
Roche's GSMapper, the CLC Genomic Workbech software, and the DNSTAR
Lasergene software are based on this design. However, for moderate or low coverage
sequencing data, this method loses valuable information and results in under-calling.
Also, this type of method does not provide a measure for the uncertainty of the
inference. Thus, several probabilistic-based methods were developed [60-65] to solve
this problem. Briefly, these methods use Bayes' formula to compute the posterior
probability for each genotype, and the one with highest posterior probability is
generally called. Then SNP is called based on the genotype calling result.
However, most of the existing SNP calling methods do not work well for the
sequencing data with low or uneven coverage. Here, we propose a simple Bayesian
approach for detecting SNPs, which is highly sensitive and specific, especially for the
low coverage sequencing data. We applied our method to a dataset from prostate cancer
cell line PC-3, which was originally obtained for epigenetic studies of histone
modifications using ChIP-Seq and thus has low and uneven coverage. Compared with
Varscan, a popular SNP calling tool that is adaptive to extreme coverage, our method
called more SNPs with higher quality. We also applied our method to two exome
sequencing datasets from colon cancer cell lines RKO and SW48 respectively, and it
shows that our method outperforms both Varscan and DNAnexus - a commercially
available SNP calling software. The genome-wide mutations of PC-3, RKO and SW48
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had not been studied previously, so our results will provide valuable information for the
future cancer study. Also, there are thousands of ChIP-Seq and RNA-Seq experiments
conducted every year, and our method can piggyback these data for the SNP analysis.
We expect our method to have a wide range of application.

3. MATIRIALS & METHODS
3.1.

Data

We applied our method to identify the SNPs of three cancer cell lines – prostate
cancer cell line PC-3, colon cancer cell lines RKO and SW48. PC-3 data was generated
by Dr. Jean- ierre Issa’s lab and sequenced with Illumina. The data was from 40 lanes
including input and Chip-seq. The details of the data source are listed in Table S1.
Totally about 109M reads with length of 30 or 36 passed the purity filter and contained
no ambiguous nucleotide such as “N”, and they were used to identify the SN s in C3.
RKO and SW48 data were from exome capture and RNA-Seq generated by Dr. Marcos
Estecio. The reads are 75bp long. 64M reads for RKO and 69M reads for SW48 were
used in our analysis.

3.2.

Base-calling error probability calculation

Illumina pipeline encodes the quality score from 0 to 62 using ASCII 64 to 126,
although only 0 - 40 could be expected in the real data. The quality score is in Phred
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format, which is related to the base-calling error probability as shown in the following
equation:

where Q is the quality score and p is the bass-calling error probability. We calculated
the accuracy of the quality scores using the PhiX data from 8 independent experiments.
Figure 3.1 shows that the reported quality score is almost identical to the empirical
quality score. Therefore, in our analysis, we used the reported quality score by Illumina
to calculate the base-calling error probability.

3.3.

Cross-talk matrix generation

For a miscalled base, the true nucleotide type is R, the probability of being
called to nucleotide type S is defined as cross-talk probability
|

{

, where

}, and

, so
. In this article,

we define the cross-talk matrix as the matrix composed of cross-talk probabilities
shown as follow:
A
A
T

T

G

C

N/A
N/A

G

N/A

C

N/A
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Figure 3.1 plot of reported quality score versus empirical quality score from the
PhiX data of 8 independent sequencing experiments. Empirical base-calling error
probability for a specified reported quality score was calculated by

, where

is the base-calling error probability for reported quality score q,
is the count of
mismatched bases with reported quality score of q, and is the total count of bases
with reported quality score of q. Then the empirical quality score could be obtained
using Eq. 3.1.
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So ∑

{

. We have proved that the cross-talk matrices for every

}

individual lane are consistent in a sequencing run. So we calculate the cross-talk matrix
for a sequenced sample by using the corresponding PhiX data in the same run. Denote
the count of bases miscalled from R to S, we calculated

with the following

equation:

∑

3.4.

{

}

Model for SNP calling

A Bayesian algorithm is applied for our SNP discovery. Basically, for a specific
genomic position, assuming that we do not know the reference genome, we calculate
the probability for each nucleotide type based on the data at this position, and the one
with largest probability is the true nucleotide. If this nucleotide is different from the
reference genome, we call it a SNP. For a given genomic position, the aligned bases are
denoted as D. We divide D into groups based on their nucleotide types. For example, if
the aligned bases are composed of three types of nucleotide – A, G and C, then D can be
divided into 3 groups – groups with nucleotide type A, G, or C respectively. Suppose
there are T groups and the tth group has
{

}

bases, then we have

. Given a nucleotide type

, where

following equation to estimate the probability whether

( | )

(

)
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{

{

}

and

}, we use the
is the true nucleotide type.

(
∑

{

)
}

( | )
∑

{

|

}

Since the reference genome is assumed to be unknown, we give equal prior probability
to each nucleotide type, which is

. Then the

above equation is simplified to
( | )

( | )

To estimate
base

{

}

( | ) in Eq. 3.3, we define

,{

between

∑

} and {

∏

as the nucleotide type for tth group. For

} respectively denote match or mismatch

’s nucleotide ty e

( | )

|

and the conditional nucleotide type

(

. Thus, we have

| )

∏∏

By pluging Eq. 3.4 into Eq. 3.3, the probability that

( | )

∏
∑

{

∏
}∏

∏
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is the true base is

Where

is the base-calling error probability for base

Eq. 3.1.

, and can be obtained from

is the cross-talk probability that is calculated from Eq. 3.2. With Eq. 3.5,

we calculate the conditional probability for each nucleotide type. The one with maximal
conditional probability is the nucleotide we detect at this position, and its corresponding
probability is denoted with . If the detected nucleotide is different from reference
genome, we define it as a SNP.

4. RESULTS
4.1.

Cross-talk study

Cross-talk is one of the major sources of error for Illumina sequencing. The
Illumina Genome Analyzer uses two lasers and four filters to detect the nucleotides
labeled with different dyes. Due to the overlap of the emission spectra of the four
fluorophores, the detected images are not independent. The intensities of A and C are
correlated as are those of G and T [66, 67]. Thus, the probabilities of miscalling for
different nucleotide types should vary.
. To control the quality and facilitate base calling, PhiX, a virus with a small
and well-defined genome containing about 45% GC and 55% AT, is sequenced together
with sequencing samples. Because of its properties, PhiX sequencing data is suitable for
the cross-talk study. Firstly, we compared the cross-talk of PhiX data from 8
independent runs. To evaluate the cross-talk, we divided the sequencing errors into
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groups based on the nucleotide types of the true base and the miscalling base, and
calculated the sequencing error rates for each group by

Where R is the nucleotide on the reference genome, and S is the aligned nucleotide from
the sequencing reads. For example, for

the numerator is the number of Cs in the

reads that are aligned to As in the reference genome, and the denominator is the total
number mismatched bases in the reads. Because

, there are totally 12 types of

and their summation should be 1. As shown in Figure 3.2, the cross-talk patterns for
different runs are not consistent. For instance,

and

are very large for data 5, but

very small for data 4. Secondly, we compared the cross-talk among different lanes in a
single run. Since PhiX is sequenced for calibration purpose, usually it only takes one
lane in a run. Thus, additionally to PhiX data, we used two lanes of reads sequenced
from E.coli to study the cross-talk among different lanes. E.coli genome is relatively
small and contains far fewer SNPs compared with Mammalian, so it is suitable for the
sequencing error study. In Figure 3.3 (a), Lane 1 and Lane 2 are from E.coli
sequencing reads, while Lane 8 is from PhiX sequencing reads in the same run.
Obviously, these three lanes share the same cross-talk pattern. Lastly, we looked at the
cross-talk for different tiles in the same lane. A lane of PhiX sequencing reads were
divided into two groups: one composed of 1-49 tiles, and one composed of 50-100 tiles.
We found that the sequencing patterns of these two groups are quite similar (Figure 3.3
(b)). Therefore, the cross-talk patterns vary for different sequencing runs, but are
consistent in each single run.
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Figure 3.2. Cross-talk patterns for different runs are not consistent. Sequencing
errors were classified for 8 sets of PhiX data from 8 independent sequencing runs. The
vertical axis is the error type based on the nucleotide type. For example, "A,C"
represents that the true nucleotide is A, but it is miscalled to C. The horizontal axis is
the relative error rate, which is calculated by
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.

Figure 3.3. Cross-talk patterns are consistent in a run. Sequencing errors were
classified in the same way as Figure 3.2. (a) We compared the cross-talk patterns of
different lanes from the same sequencing run. Lane 1 and Lane 2 were sequenced from
E.coli genome. Lane 8 is sequenced from PhiX. (b) A single lane of PhiX sequencing
data was divided into two groups based on tiles. The cross-talk patterns of these two
groups are consistent.
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4.1.

Model testing with PhiX data

We tested our method with the PhiX data by manually mutating some positions
on the PhiX genome, and using the mutated genome as the reference genome. Thus, the
mutated positions serve as the gold standard of SNP sites. As shown in Figure 3.4, the
coverage of the PhiX genome by the sequencing reads is high and uniform. The average
sequencing depth is about 73. We applied our method to this dataset, and compared our
results with the gold standard mutations (Figure 3.5). The SNPs called by our method
exactly match the gold standard. All the SNPs were correctly called, and no false
positive SNPs were observed.

4.1.

SNPs detection for prostate cancer cell line PC-3

Prostate cancer usually occurs in old men, and is the most common cause of
death from cancer in men over age 75. PC-3 is a human prostatic carcinoma cell line,
which is initiated from a bone metastasis of a grade IV prostatic adenocarcinoma from a
62-year-old man [68, 69]. PC-3 is near-triploid with a modal number of 62
chromosomes. PC-3 has a unique karyotype. Normal chromosomes N2, N3, N4, N5,
N12, and N15 are absent. The mutation status of PC-3 is still unknown. The PC-3 data
we obtained were originally generated for the epigenetic studies of histone modification
with ChIP-Seq, so its coverage is low and uneven. Therefore, PC-3 dataset is perfect for
testing the performance of our method on low coverage data.
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Figure 3.4. Genome coverage of PhiX by the sequencing reads used for testing our
method. The coverage is high and uniform. Average coverage is about 73, which is
shown as the blue line.
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Figure 3.5 Comparison of the gold standard mutations and the SNPs detected by
our method. The cyan color represents the gold standard mutations we generated, and
the orange color represents the SNPs we detected. The mutations we generated are
identical to the mutations detected by our methods.
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4.2.1.

Coverage of PC-3 sequencing data

We aligned the reads of PC-3 dataset with Bowtie's v-mode by allowing up to 3
mismatches for the whole read [56], and calculated the coverage for different regions in
human genome with BEDTools [70]. There are many gaps in the reference human
genome, which cannot be sequenced or mapped. The largest gaps exist in the highly
repetitive regions of the genome - mostly around the centromeres and other
heterochromatic regions. Some gaps also locate at gene clusters. To obtain an accurate
coverage, we subtracted these gaps from the reference genome and used the gapless
genome in the calculation. As shown in Table 3.1, ~50% of the genome is sequenced,
and most of the sequencing reads aligned to the non-exonic regions. ~ 90% of the
sequenced positions are covered with 4 or fewer reads, and only < 5% of the sequenced
positions are covered with 6 or more reads (Figure 3.6). The average sequencing depths
for different regions are less than 3, while the maximum sequencing depths are very
large, indicating that the coverage is low and uneven. The average sequencing depth
here is the average from the covered positions.

4.2.1.

Characterization of the identified SNPs for PC-3

To assess the specificity of our method, we compared the identified SNPs with
dbSNP (Single Nucleotide Polymorphism Database) and 1000-genome database.
dbSNP is a free public archive for genetic variation developed and hosted by NCBI.
Until now, most variants have been catalogued by dbSNP. Since most genetic variants
in one individual should have been previously observed from other people, usually
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Table 3.1 Coverage of PC-3 dataset
Sequencing depth

Covered regions

Maximum

Average

Number of bases (Mb)

Percentage

Whole-genome

12429

1.2

1419.7

49.60%

Gene region

771

1.3

1276.3

52.70%

Exome

771

2.6

83.2

66.30%

CDS (coding sequence)

348

2.6

41.7

72.80%
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Figure 3.6 The distribution of the sequencing depth of PC-3 dataset in the whole
genome. (a) Density distribution: the proportion of covered positions at different
sequencing depth. (b) Cumulative distribution: proportion of the positions covered at
equal or less than specified depth. So the sequencing depth is very low, and about 95%
of the sequenced genome is covered with 6 or fewer reads. Note that the proportion here
is calculated with respect to the positions with at least one read aligned.
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dbSNP is used as the standard to measure the specificity of SNP detection. dbSNP has
been constantly updated, so >90% of the SNPs are expected to be discovered in dbSNP .
Although the presence in dbSNP does not absolutely confirm the authenticity of the
SNP, since the dbSNP build 135 contains 47.8 million SNPs (only 1.6% of the whole
genome) , the relative difference between call sets should be able to reflect the quality
differences. Similarly to dbSNP, 1000-genome database is also a large public variation
data resource, which is established by sequencing the genomes of a large number of
people. The current 1000-genome database contains 38 million SNPs (1.3% of the
whole genome). In this article, we use dbSNP rate as the percentage of the SNPs
discovered in dbSNP, and use 1000-genome rate as the proportion of the SNPs
described in 1000-genome database.
The majority of the SNPs in PC-3 detected by our method are previously
described by dbSNP and 1000-genome database, suggesting that our method works very
well on PC-3 data. As shown in Figure 3.7(a) and Figure 3.8(a), the dbSNP rate and
1000-genome rate increase when the cutoff of the SNP allele count increases. For the
SNPs with allele counts equal or larger than 3, over 90% of the SNPs are discovered in
the dbSNP or 1000-genome database. Recall that  denotes the conditional probability
of called SNP. With the increase of  value, the dbSNP rate and 1000-genome rate also
increase (Figure 3.7(b) and Figure 3.8(b)).
To improve the SNP calls, we use the product of allele count and  to control
the quality. SNPs with

below the cutoff value will be removed from

the final result. Setting the cutoff too large will miss a lot of true SNPs, while setting the
cutoff too small will produce many false positive SNPs. Thus, varying the value of this
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(a)

(b)

Figure 3.7 Comparison of PC-3 SNPs detected with our method to dbSNP. With the
increase of cutoff for (a) SNP allele count and (b)  value, dbSNP rate increases.
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(a)

(b)

Figure 3.8 Comparison of PC-3 SNPs detected with our method to 1000-genome
database. With the increase of cutoff for (a) SNP allele count and (b)  value, 1000genome rate increases.
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Figure 3.9 Removing the Duplicates slightly increase the dbSNP rate. At various
cutoff point of allele-count * , the dbSNP rates after removing the duplicates become
higher.
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cutoff value results in a trade-off between sensitivity and specificity. For PC-3 data, to
balance the sensitivity and specificity, we set the cutoff value to 2, with which about
94.4% of SNPs overlap with dbSNP (Figure 3.9).
Duplicate reads contribute to the false positive SNPs. When the sequencing
library preparation involved the PCR amplification step, duplicated reads are usually
observed. Duplicate reads from PCR amplification usually results in areas of high
disproportional high coverage, and are often the cause of false positive in SNP calling,
especially when the replication errors are made by the enzymes during the amplification.
So we removed the duplicate reads that share common coordinates, sequencing
direction and same sequence. The effect of removing duplicates varies in different
datasets. For PC-3, removing the duplicates slightly improved the SNP calling, and the
improvement becomes more significant when the cutoff value increases (Figure 3.9). It
is reasonable because the PC-3 data is from many experiments and the majority of the
PC-3 covered positions has low sequencing depth, indicating that the duplicate rate is
low. The duplicate rate is larger for the positions with higher sequencing depth, so the
effect of removing duplicates is more significant for higher depth.

4.2.2.

Comparison with other SNP detection tools

To evaluate the performance of our method, especially its ability of detecting
SNPs from low coverage data, we compared our method with Varscan - a very popular
variant-calling method, which has the adaptability to extreme read depth and pooled
samples. It employs a robust heuristic/statistic approach to call variants. With optimized
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setting for the parameters, Varscan called 115,571 SNPs, of which 101,736 are
observed in dbSNP. Our method detected 526,925 SNPs and 497,526 of them are
discovered in dbSNP (Table 3.2). So our method found about 4.5 times more SNPs
than Varscan, while maintaining a higher dbSNP rate (94.42% versus 88.03%),
indicating that our method is more sensitive and specific than Varscan for PC-3 data.
Transition/transversion ratio (Ti/Tv) is a critical metric to assess the specificity
of SNP-calling. Transition is the substitution of a purine by a purine or a pyrimidine by
a pyrimidine (
vice versa (

). Transversion is a change from purine to pyrimidine, or
). Ti/Tv is 0.5 when there is no bias towards

either transition or transversion, because the two kinds substitutions are equal probable,
and there are twice as many transversions than transitions. However, for all the
genomes examined so far, transitions occur more frequently than transversions [73-77].
Ti/Tv is known to be a general property of DNA sequence evolution. Inter-species
comparison and previous sequencing projects showed that the Ti/Tv for the genomewide variants is ~2.0-2.1, and the exonic Ti/Tv is ~3.0-3.5 [78, 79]. Given the observed
Ti/Tv, the false discovery rate (FDR) can be obtained by

where the

is the expected value of Ti/Tv. We let

equal

2.05 for whole genome and 3.25 for exome. As shown in Table 3.2, Ti/Tv obtained by
our method is 1.98, which is more close to the standard genome-wide Ti/Tv (2.0-2.1)
than the Varscan Ti/Tv (1.68). Also, the FDR of our method is only 0.04, which is
<0.05 and much better than the Varscan FDR (0.24).
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Table 3.2 Comparison of our method with Varscan for PC-3 data. In the calculation
of FDR, 2.05 is used as the expected Ti/Tv ratio.
our method

Varscan

Number of called SNPs

526,925

115,571

Number of SNPs observed in dbSNP

497,526

101,736

dbSNP rate (%)

94.42

88.03

Ti/Tv ratio

1.98

1.68

FDR

0.04

0.24
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4.2.3.

Annotation of SNPs in PC-3

We annotated the SNPs with ANNOVAR - a tool for functionally annotating the
genetic variants [80]. Based on the function of the DNA sequences where the SNPs
aligned, SNPs are classified as intergenic SNPs, intronic SNPs, exonic SNPs, splicing
site SNPs, upstream/downstream SNPs, 5' / 3' UTR (untranslated region) SNPs, and
ncRNA (non-coding RNA) SNPs. Here, splicing site SNP is the SNP within 2-bp of a
splicing junction, and upstream/downstream SNP is the SNP overlaps 1-kb region
upstream/downstream of transcription start/end site. Consistent to the distribution of the
sequencing reads of PC-3, most of the SNPs detected by our method are in intergenic
and intronic regions (Figure 3.10 (a) ). We also found that the dbSNP rates of different
regions vary (Figure 3.10 (b) ). The splicing site SNPs for both RNA and ncRNA have
lower dbSNP rates than the other regions. The detailed numbers are listed in Table 3.3
(a). Based on the effect of the substitution to the genetic coding, exonic SNPs are
further grouped into synonymous SNPs, nonsynonymous SNPs, stopgain SNPs,
stoploss SNPs, and unknown SNPs (Table 3.3 (b) ). Stopgain SNPs are very important,
because they result in truncated, incomplete, and usually nonfunctional protein product.
There are four novel stopgain SNPs and one novel stoploss SNP discovered in PC-3
data (Table S2 ).
To identify the potential causal genes responsible for the prostate cancer, we
prioritized the SNPs in several steps (Figure 3.11). Although exons only constitute
about 1% of the human genome [15], it is estimated that the protein coding regions
constitute about 85% of the disease-causing variants [81]. There is also highly
functional variation in the splicing sites [82], so we first perform a gene-based
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(a)

downstream
exonic
exonic;splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream;downstream
UTR3
UTR5
UTR5;UTR3

(b)

discovered in dbSNP

not discovered by dbSNP

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Figure 3.10. (a) Pie chart of PC-3 SNPs for different genome regions. (b)
Percentage of SNPs observed in dbSNP for different regions.
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Table 3.3 Classification of PC-3 SNPs.
(a) Classification of PC-3 SNPs by genome region.

downstream
exonic
exonic; splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream; downstream
UTR3
UTR5
UTR5;UTR3

Number of called
SNPs
3,361
6,243
60
304,694
184,877
1,505
13,178
7
66
30
49
6,305
199
3,948
2,400
3

Number of SNPs
observed in dbSNP
3,206
5,839
54
284,260
177,945
1,424
12,542
6
63
30
36
5,961
183
3,780
2,194
3

dbSNP rate
(%)
95.39
93.53
90.00
93.29
96.25
94.62
95.17
85.71
95.45
100.00
73.47
94.54
91.96
95.74
91.42
100.00

(b) Classification of exonic SNPs of PC-3 by genetic coding.
Number of called SNPs

Number of SNPs observed in dbSNP

nonsynonymous

2,991

2,735

synonymous

3,169

3,029

stopgain

25

21

stoploss

3

2

unknown

115

106
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Figure 3.11. Prioritization of causal genes for PC-3.
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annotation to identify 526,925 SNPs locating at exons or splicing sites. We then filtered
the SNPs from 1000-genome database, ESP (NHLBI GO Exome Sequencing Project)
6500 database, dbSNP135 database and CG (Complete Genomics) 69 database,
assuming that the SNPs observed in public databases are less likely to be causal SNPs
of cancer. ESP is to discover novel genes and mechanism contributing to the lung, heart
and blood disorder, and its database is constituted of the variants sequenced from 6500
exomes of the human genome across diverse, richly-phenotyped populations. CG69 is
the variant database established by Complete Genomics Company by sequencing 69
whole human genomes. The novel SNPs were then scored by SIFT [83] and PolyPhen
[84] - tools to predicts the importance of variants to the protein function. Generally,
SN s with SIFT score ≤ 0.05 or oly hen score ≥ 0.85 are redicted to be deleterious.
Totally, 131 SNPs passed all the filters and 107 genes were identified as the causal
genes, of which the detail information is listed in Table S3.

4.2.

SNPs detection for colon cancer cell lines RKO and SW48

American Cancer Society reported that colon cancer is one of the leading causes
of cancer-related deaths in the United States. However, colon cancer can often be
completely cured with early diagnosis. Identification of the causal variants for colon
cancer may greatly contribute to the early diagnosis, and therefore can be particularly
significant. RKO and SW48 are two colon cancer cell lines that are used as in vitro
models for colorectal cancer to study biochemical mechanisms of carcinoma formation.
However, the mutation statuses of RKO and SW48 remain unknown. On the other hand,
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exome sequencing is the most popular sequencing strategy for the variants detection.
Compared with the whole genome sequencing, exome sequencing is cheaper but still
effective, because exome is usually more straightforwardly related to the diseases.
Different from whole genome sequencing, exome sequencing data usually has higher
coverage and contains more duplicates. Here, we applied our method to detect the SNPs
in RKO and SW48 cell lines, not only showing the performance of our method on the
exome sequencing data, but also providing valuable information for the future colon
cancer study.

4.3.1.

Coverage of RKO and SW48 sequencing data

RKO and SW48 are sequenced by exome capture and RNA-seq, so most of the
reads align to the exome. The coverage of PKO and SW48 data are similar (Table 3.4),
because same protocols were applied in the experiments. ~ 60% of exome and ~ 80% of
CDS region are sequenced, with the average sequencing depths of ~65 for exome and
~35 for CDS. Compared with PC-3 data, the sequencing depths of RKO and SW48 are
much higher and more evenly distributed. ~95% of the sequenced positions are covered
by 1-200 reads (Figure 3.12).

4.3.1.

Characterization of the identified SNPs for RKO and SW48

Similar to PC-3 data, the dbSNP rates and 1000-genome rates of RKO and
SW48 also positively relate to the SNP allele count and  value. With an appropriate
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Table 3.4 Coverage of RKO and SW48 dataset.
sequencing depth

covered regions

maximum

average

number of bases (Mb)

percentage

Exome

293,247

35.5

76.2

60.67%

CDS

63,609

64.7

47.2

82.36%

Exome

329,032

34.7

79.2

63.12%

CDS

86,703

63.2

48.1

83.96%

RKO

SW48
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Figure 3.12 The distribution of the sequencing depth of RKO and SW48 datasets
in the CDS region. (a) Density distribution: proportion of the covered positions at
different sequencing depths. (b) Cumulative distribution: proportion of the positions
covered at equal or less than specified depth. Therefore, majority of the sequencing
depths almost uniformly distributed in from 1-100, and ~95% of the CDS region has ≤
reads aligned. Note that the proportion here is calculated with respect to the positions in
CDS that are covered with at least one read.
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cutoff for the product of SNP allele count and  value, we identified 95,142 SNPs for
RKO, of which 76,836 are discovered in dbSNP. Similarly, 101,088 SNPs are detected
from SW48 dataset, and 76,560 of them are overlapped with dbSNP. The dbSNP rates
are 80.76% and 80.90% respectively.
The effect of the duplicate reads was measured. After the duplicate reads are
removed, the dbSNP rates show a trend to increase (Figure 3.13). Compared with PC-3,
the increases for RKO and SW48 are more significant. PC-3 dataset is from many
experiments with low sequencing depth, so the duplicate rate is low. RKO and SW48
datasets contain exome sequencing reads which usually have high duplicate rate.
Therefore, removing duplicates could highly improve the SNP calling quality for RKO
and SW48 datasets.

4.3.2.

Comparison with other SNP detection tools

To evaluate the performance of our method on exome capture data, we also ran
the RKO and SW48 dataset with Varscan and DNAnexus. DNAnexus is a commercial
software for NGS analysis including variation detection. For RKO, Varscan detects
101,088 SNPs with 76,560 overlapped with dbSNP (Table 3.5). Compared with
Varscan, our method detects ~300 more possibly right variants (variants described in
dbSNP) and obtains higher dbSNP rate (80.76% versus 75.74%). Our method also
outperforms DNAnexus on SNPs detection. DNAnexus detects much fewer SNPs in
dbSNP (52,923), and the dbSNP rate (59.57%) is much lower than our method
(80.76%). The Ti/Tv ratios of Varscan and our method are higher than that of
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Figure 3.13 Removing the Duplicates increase the dbSNP rate significantly. At
various cutoff point of allele-count * , the dbSNP rates after removing the duplicates
become higher.
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Table 3.5 Comparison of different tools for calling SNPs in RKO and SW48 cell
lines.

RKO

our method

Varscan

DNAnexus

total SNP

95,142

101,088

88,849

SNPs in dbSNP

76,836

76,560

52,923

dbSNP rate (%)

80.76

75.74

59.57

Ti/Tv ratio

2.15

2.22

1.38

FDR

0.10

0.07

0.52

total SNP

113,195

121,494

94,958

SNPs in dbSNP

92,706

86,014

56,862

dbSNP rate (%)

81.90

70.80

59.88

Ti/Tv ratio

2.13

2.07

1.42

FDR

0.09

0.13

0.49

(
SW48

(

= 2.34)

= 2.3)
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DNAnexus, which is consistent to the dbSNP rates. Note that even the Ti/Tv ratios
calculated by Varscan and our method are only ~ 2.2, which is far smaller than the
expected Ti/Tv ratio for exome (3.0-3.5). This is because that in the RKO and SW48
datasets a lot of reads are from non-exonic region, reducing the Ti/Tv ratio. The Ti/Tv
ratio for the SNPs described in dbSNP is ~2.3, proving that the low Ti/Tv ratio is not
caused by inaccurate call. Since ~ 75% of the SNPs are from intronic and intergenic
region, we modify

to 2.34 according the percentage of exonic SNPs in

total SNPs. The FDRs calculated with the modified

are consistent with

the dbSNP rates. Similar results are obtained for SW48.

4.3.3.

Annotation and comparison of SNPs in RKO and SW48

We compared the SNPs of RKO and SW48, and found 32,224 SNPs in common,
which is 33.87% and 28.47% of SNPs in RKO and SW48 respectively. Among these
common SNPs, 28,326 (87.90%) SNPs are found in dbSNP (Table 3.6). With the same
method we applied to PC-3, we annotate the SNPs in RKO and SW48 and classified
them by their functions, then we found that SNPs from these two datasets distribute in a
very similar pattern (Figure 3.14 (a) ), which is possibly because these two datasets
share the same experiment protocol. ~ 50%-60% SNPs are intronic and 20% SNPs are
intergenic, which explained the low Ti/Tv ratios. Only about 15% SNPs are from
exome. The dbSNP rate varies for the SNPs with different functions (Figure 3.14 (b)).
Similar to PC-3 data, the dbSNP rate for splicing SNPs are much lower than the others.
Exonic SNPs are grouped by their effect to genetic coding (Table 3.7). 47 stopgain
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Table 3.6 Classification of RKO and SW48 SNPs and their common SNPs.
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RKO

downstream
exonic
exonic;splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream;downstream
UTR3
UTR5
UTR5;UTR3

SW48

downstream
exonic
exonic;splicing
intergenic
intronic
ncRNA_exonic
ncRNA_intronic
ncRNA_splicing
ncRNA_UTR3
ncRNA_UTR5
splicing
upstream
upstream;downstream
UTR3
UTR5

Figure 3.14 (a) Pie charts of RKO and SW48 SNPs for different genome regions.
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RKO

discovered in dbSNP

not discovered by dbSNP

discovered in dbSNP

not discovered by dbSNP

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

SW48
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Figure 3.14 (b) Percentage of RKO and SW48 SNPs observed in dbSNP for
different regions.
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Table 3.7 Classification of exonic SNPs in RKO and SW48 by genetic coding.
RKO

SW48

common

total

in dbSNP

total

in dbSNP

total

in dbSNP

nonsynonymous

5,563

4,781

4,814

4,195

2,230

2,201

synonymous

6,070

5,738

5,393

5,141

2,566

2,552

stopgain

47

24

54

27

12

12

stoploss

8

8

9

7

2

2

unknown

54

48

65

55

26

24
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SNPs are found for RKO, and 54 stopgain SNPs are found for SW48. Among these
stopgain SNPs, 12 SNPs are in common. Novel stopgain and stoploss SNPs that are not
discovered in dbSNP are listed in Table S4.
To identify the potential causal genes for RKO and SW48, we applied the same
method used for PC-3 to prioritize the SNPs (Figure 3.15). The exonic/splicing
nonsynonymous SNPs are filtered with 1000-genome database, ESP6500 database,
dbSNP135 database and CG69 database. Furthermore, the SNPs that are believed to be
benign by SIFT and PolyPhen are removed. For RKO and SW48, we found 1188 and
1213 SNPs respectively, which correspond to 701 and 652 genes. 292 genes are in
common for RKO and SW48.

5. DISCUSSION
The high throughput of NGS provides the possibility to completely study the
genome-wide variation, but it also challenges the algorithms for variants detection due
to its high sequencing error rates. Most SNP calling methods work well for the highcoverage data, so exome sequencing is the most common strategy for the variants study.
Exome is the major disease-causing region but only constitutes about 1% of the human
genome, so exome can be sequenced deeply without extra cost. However, exome
sequencing is only able to detect the variants in the coding region of genes which
control the protein function. It is unable to detect the variants from the remained 99% of
the human genome, which can affect the gene regulatory and are also associated with
diseases. But sequencing the whole genome deeply is not practical right now due to the
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Figure 3.15. Prioritization of causal genes for RKO and SW48.
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high cost. Therefore, we report a novel SNP calling algorithm which can achieve high
sensitivity and specificity for low coverage data. We have showed that our method
perform well on both low coverage ChIP-Seq data and high coverage Exome
sequencing data. There are thousands of ChIP-Seq data, RNA-Seq data and some other
sequencing data with low or uneven coverage conducted every year, which can also be
used for the SNP detection with our method. We expect that by utilizing these data, the
catalogue of the human genetic variants will grow fast.
A few verified SNPs have been reported for RKO and SW48. RKO has two
verified substitutions: c.1799T>A in BRAF gene and c.3140A>G PIK3CA gene. The
first one is shown in our result, but the second was not called because it is the allele
with lower frequency and our method only report the primary allele. SW48 also has two
verified substitutions: c.98C>A in CTNNB1 gene and c.2155G>A in EGFR gene.
Similar to RKO, the first one was identified by our method, but the second one was not
called because of its low frequency. The comparison between the verified SNPs and our
results shows the reliability of our method. In this article, we only showed the SNPs that
are the primary alleles, but our method can also be used to call the alternative allele by
reporting the allele with second higher probability. Furthermore, our method is also able
to call genotype using the ratio of the highest and second highest probability.
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CHAPTER FOUR

Conclusion
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In this article, we first present an algorithm that is highly robust and efficient at
correcting errors in the NGS data. We demonstrated the effectiveness of MTM on both
single-cell data with highly non-uniform coverage and normal data with uniformly high
coverage, reflecting that MTM does not rely on the coverage of the sequencing reads.
Compared with the previous tools Hammer and Quake, which beat the other tools on
non-uniform and uniform data respectively, MTM showed better performance than
Hammer and better or similar performance than Quake in terms of the positive
predictive value and sensitivity. We also showed the benefits of error correction with
MTM on the downstream analysis, such as mapping and SNP detection.
We then present a Bayesian-based approach for SNP calling, which improved
the existing methods by having no limitation on the sequencing depth. We successfully
applied this approach to identify the SNPs in prostate cancer cell line PC-3 and colon
cancer cell lines RKO and SW48, whose mutation status are unknown. Our method
outperforms the existing methods - Varscan and DNAnexus - by identifying more SNPs
while maintaining higher dbSNP rates, especially for the low coverage PC-3 data. In
summary, we identified 107 potential causal genes for PC-3. For RKO and SW48 cell
lines, 701 and 652 potential causal genes were identified respectively, and 297 genes
are in common. With the ability of piggybacking on the ChIP-Seq, mRNA-Seq and
other sequencing data with low or uneven coverage, this approach is expected to have a
wide range of applications.
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Table S1. Data source of PC3 used in SNPs identification.
Data ID

090218_HWUSI-EAS182R_0001_30KPG

090220_HWUSI-EAS182R_0002_30KR3

090512_HWUSI-EAS230-R_0003_30NYJ

090526_HWUSI-EAS230-R_0006_30P04

090327_HWUSI-EAS182R_0006_30M3H

090327_HWUSI-EAS182R_0006_30MKR

090526_HWUSI-EAS230-R_0006_30P04

111

Lane #
1
2
3
4
5
6
7
1
2
3
4
5
6
7
1
2
3
4
5
6
7
1
2
3
4
5
6
3
4
5
6
7
1
2
3
4
5
7

Cell line
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3
PC3

Experiment
LMN
Pol2
H3K4me3
H3K9me2
H3K27me3
AGO2
Total_H3
LMN
Pol2
H3K4me3
H3K9me2
H3K27me3
AGO2
H3
LMN
Pol2
H3K4me3
H3K9me2
H3K27me3
AGO2
Total_H3
H3K9me2
H3K9me2
H3K9me2
H3K9me3
H3K9me3
H3K9me3
input
H3
H3K4me3
H3K27me3
input
input
H3
H3K4me3
H3K27me3
input
H3K27me3

090507_HWUSI-EAS230-R_0002_30NWT
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6
7

PC3
PC3

H3
H3K4me3

Table S2. Noval stopgain and stoploss SNPs for PC-3
function

chromosome

position

ref

SNP

stopgain

chr3

160155983

A

T

stopgain

chr12

56647988

C

A

stopgain

chr16

1822802

G

A

stopgain

chr19

50916763

C

A

stoploss

chr19

35633644

T

G
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Gene information
TRIM59:NM_173084:exon3:c.
T989A:p.L330X,
ANKRD52:NM_173595:exon8
:c.G769T:p.E257X,
MRPS34:NM_023936:exon1:c
.C319T:p.Q107X,
POLD1:NM_001256849:exon1
8:c.C2235A:p.Y745X,POLD1:
NM_002691:exon18:c.C2235A
:p.Y745X,
FXYD1:NM_005031:exon7:c.
T277G:p.X93E,FXYD1:NM_0
21902:exon7:c.T277G:p.X93E,

Table S3. Potential causal genes identified by our method for PC-3
Gene
Symbol
CTBP2

SNPs
number
3

Entrez Gene Name

Location

Type(s)

C-terminal binding protein 2

Nucleus

2

zinc finger protein 717

Nucleus

transcription
regulator
other

ZNF717
NOXO1

2

NADPH oxidase organizer 1

ALG9

2

KIR2DL3

2

RARRES2

2

CHD8

2

SNX18

2

asparagine-linked glycosylation 9, alpha1,2-mannosyltransferase homolog (S.
cerevisiae)
killer cell immunoglobulin-like receptor,
two domains, long cytoplasmic tail, 3
retinoic acid receptor responder
(tazarotene induced) 2
chromodomain helicase DNA binding
protein 8
sorting nexin 18

UNC80

2

CCDC57
DUSP28

Plasma
Membrane
Cytoplasm

other
enzyme

Plasma
Membrane
Plasma
Membrane
Nucleus

transmembrane
receptor
enzyme

Cytoplasm

transporter

unc-80 homolog (C. elegans)

unknown

other

2

coiled-coil domain containing 57

unknown

other

2

dual specificity phosphatase 28

unknown

enzyme

PTPRM

2
2

Plasma
Membrane
Cytoplasm

phosphatase

LLGL1
FAM174B

2

unknown

other

VEPH1

1

Nucleus

other

MMS19

1

Nucleus

FREM3

1

protein tyrosine phosphatase, receptor
type, M
lethal giant larvae homolog 1
(Drosophila)
family with sequence similarity 174,
member B
ventricular zone expressed PH domain
homolog 1 (zebrafish)
MMS19 nucleotide excision repair
homolog (S. cerevisiae)
FRAS1 related extracellular matrix 3

transcription
regulator
other

IFI35

1

interferon-induced protein 35

PLD4

1

phospholipase D family, member 4

URB1

1

GATA2

1

URB1 ribosome biogenesis 1 homolog
(S. cerevisiae)
GATA binding protein 2

DAPP1

1

DSE

1

dual adaptor of phosphotyrosine and 3phosphoinositides
dermatan sulfate epimerase

RUNX3

1

EYS

Extracellular
Space
Nucleus

other

other

other

Extracellular
Space
Nucleus

enzyme

Nucleus
Cytoplasm

transcription
regulator
other

Cytoplasm

enzyme

runt-related transcription factor 3

Nucleus

1

eyes shut homolog (Drosophila)

unknown

transcription
regulator
other

THAP3

1

unknown

other

RBMXL3

1

unknown

other

NTN3

1

THAP domain containing, apoptosis
associated protein 3
RNA binding motif protein, X-linked-like
3
netrin 3

Extracellular
Space

other
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other

FEM1A

1

fem-1 homolog a (C. elegans)

Nucleus

RAP2A

1

DMRT1

1

TMC2

1

RAP2A, member of RAS oncogene
family
doublesex and mab-3 related transcription
factor 1
transmembrane channel-like 2

OBSCN

1

EIF4G2

1

AEN

1

obscurin, cytoskeletal calmodulin and
titin-interacting RhoGEF
eukaryotic translation initiation factor 4
gamma, 2
apoptosis enhancing nuclease

GFM2

1

G elongation factor, mitochondrial 2

Cytoplasm

COPB2

1

Cytoplasm

OR4D9

1

coatomer protein complex, subunit beta 2
(beta prime)
olfactory receptor, family 4, subfamily D,
member 9

KIF5C

1

kinesin family member 5C

Cytoplasm

G-protein
coupled
receptor
other

CDC27

1

Nucleus

other

SGPP2

1

cell division cycle 27 homolog (S.
cerevisiae)
sphingosine-1-phosphate phosphatase 2

Cytoplasm

phosphatase

CTBP1

1

C-terminal binding protein 1

CUL9

1

cullin 9

UTP18

1

C17orf100

1

UTP18 small subunit (SSU) processome
component homolog (yeast)
chromosome 17 open reading frame 100

Plasma
Membrane
Nucleus
Plasma
Membrane
Cytoplasm
Cytoplasm
Nucleus

Plasma
Membrane

transcription
regulator
enzyme
transcription
regulator
other
kinase
translation
regulator
enzyme
translation
regulator
transporter

Nucleus

enzyme

Cytoplasm

other

Nucleus

other

unknown

other

DUSP5

1

dual specificity phosphatase 5

Nucleus

phosphatase

EPPK1

1

epiplakin 1

Cytoplasm

other

RHPN1

1

rhophilin, Rho GTPase binding protein 1

Cytoplasm

other

MLL3

1

Nucleus

AP2A1

1

Cytoplasm

transcription
regulator
transporter

LRRIQ1

1

unknown

other

CATSPER
1
PRSS56

1

myeloid/lymphoid or mixed-lineage
leukemia 3
adaptor-related protein complex 2, alpha
1 subunit
leucine-rich repeats and IQ motif
containing 1
cation channel, sperm associated 1

ion channel

1

protease, serine, 56

Plasma
Membrane
unknown

ODZ2

1
1

Plasma
Membrane
Cytoplasm

other

MYH2
SNED1

1

odz, odd Oz/ten-m homolog 2
(Drosophila)
myosin, heavy chain 2, skeletal muscle,
adult
sushi, nidogen and EGF-like domains 1

G6PD

1

glucose-6-phosphate dehydrogenase

ONECUT
3
KLC1

1

one cut homeobox 3

Nucleus

1

kinesin light chain 1

Cytoplasm

transcription
regulator
other

NLK

1

nemo-like kinase

Nucleus

kinase
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Plasma
Membrane
Cytoplasm

other

enzyme
other
enzyme

MUC2

1

mucin 2, oligomeric mucus/gel-forming

unknown

other

C11orf9

1

chromosome 11 open reading frame 9

Nucleus

C17orf105

1

chromosome 17 open reading frame 105

unknown

transcription
regulator
other

SERINC4

1

serine incorporator 4

unknown

other

PPP4C

1

protein phosphatase 4, catalytic subunit

Cytoplasm

phosphatase

C1orf172

1

chromosome 1 open reading frame 172

unknown

other

ABCA6

1
1

CLDN3

1

claudin 3

ERCC3

1

TTLL3

1

KCNH2

1

MVP

1

excision repair cross-complementing
rodent repair deficiency,
complementation group 3
tubulin tyrosine ligase-like family,
member 3
potassium voltage-gated channel,
subfamily H (eag-related), member 2
major vault protein

Plasma
Membrane
Extracellular
Space
Plasma
Membrane
Nucleus

transporter

FBLN2

ATP-binding cassette, sub-family A
(ABC1), member 6
fibulin 2

MUC6

1

mucin 6, oligomeric mucus/gel-forming

FAM179A

1

GRID1

1

family with sequence similarity 179,
member A
glutamate receptor, ionotropic, delta 1

LHX3

1

LIM homeobox 3

VWF

1

von Willebrand factor

CTDSP2

1

HK3

1

CTD (carboxy-terminal domain, RNA
polymerase II, polypeptide A) small
phosphatase 2
hexokinase 3 (white cell)

PELP1

1

PREX2

1

ISYNA1

1

KCNG2

1

PCNXL2

Extracellular
Space
Plasma
Membrane
Nucleus

other
transmembrane
receptor
enzyme

enzyme
ion channel
other

Extracellular
Space
unknown

other

Plasma
Membrane
Nucleus

ion channel

Extracellular
Space
Nucleus

other

transcription
regulator
other
phosphatase

Cytoplasm

kinase

proline, glutamate and leucine rich
protein 1
phosphatidylinositol-3,4,5-trisphosphatedependent Rac exchange factor 2
inositol-3-phosphate synthase 1

Nucleus

other

Cytoplasm

other

unknown

enzyme

Plasma
Membrane
unknown

ion channel

1

potassium voltage-gated channel,
subfamily G, member 2
pecanex-like 2 (Drosophila)

HOXD10

1

homeobox D10

Nucleus

DUX4

1

double homeobox 4

Nucleus

FSCN1

1

Cytoplasm

ELFN1

1

unknown

other

ZNF649

1

fascin homolog 1, actin-bundling protein
(Strongylocentrotus purpuratus)
extracellular leucine-rich repeat and
fibronectin type III domain containing 1
zinc finger protein 649

transcription
regulator
transcription
regulator
other

Nucleus

other
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other

RYR1

1

ryanodine receptor 1 (skeletal)

Cytoplasm

ion channel

TMEM59
L
ABCF3

1

transmembrane protein 59-like

Cytoplasm

other

1

unknown

transporter

MUC16

1

ATP-binding cassette, sub-family F
(GCN20), member 3
mucin 16, cell surface associated

unknown

other

PPM1N

1
1

ANKRD52

1

ankyrin repeat domain 52

Extracellular
Space
Extracellular
Space
Nucleus

other

C7

protein phosphatase, Mg2+/Mn2+
dependent, 1N (putative)
complement component 7

FOXA1

1

forkhead box A1

WDR34

1

WD repeat domain 34

FAM59B

1

TPST2

1

family with sequence similarity 59,
member B
tyrosylprotein sulfotransferase 2

ISLR2

1

FAT1

1

SAMD11

1

immunoglobulin superfamily containing
leucine-rich repeat 2
FAT tumor suppressor homolog 1
(Drosophila)
sterile alpha motif domain containing 11

other

Cytoplasm

transcription
regulator
transcription
regulator
other

unknown

other

Cytoplasm

enzyme

Plasma
Membrane
Plasma
Membrane
Nucleus

other

Nucleus

other
other

SSPO

1

SCO-spondin homolog (Bos taurus)

Cytoplasm

other

KRTAP7

1

unkonwn

unknown

unknown

HLA

1

unkonwn

unknown

unknown
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Table S4. Noval stopgain and stoploss SNPs in RKO and SW48
(a) Noval stopgain and stoploss SNPs in RKO
function

chromosome

position

reference

SNP

Gene information

stopgain

chr1

152185725

G

A

stopgain

chr2

85255047

C

T

stopgain

chr2

220160985

C

T

stopgain

chr3

40211492

G

T

stopgain

chr3

98109948

G

T

stopgain

chr4

56225592

G

T

stopgain

chr5

16671018

G

A

stopgain

chr5

140579957

G

T

stopgain

chr6

52696720

G

A

stopgain

chr6

152457756

G

T

stopgain

chr10

5773040

C

T

stopgain

chr12

85279758

G

A

stopgain

chr12

112330854

G

T

stopgain

chr13

47361163

C

T

stopgain

chr14

73491163

G

T

stopgain

chr16

50745326

C

T

stopgain

chr17

7186639

C

T

stopgain

chr17

27049838

A

T

stopgain

chr17

62856696

C

A

HRNR:NM_001009931:exon3:c.
C8380T:p.Q2794X,
KCMF1:NM_020122:exon2:c.C5
2T:p.R18X,
PTPRN:NM_001199764:exon18:
c.G2201A:p.W734X,PTPRN:NM
_001199763:exon17:c.G2384A:p
.W795X,PTPRN:NM_002846:ex
on18:c.G2471A:p.W824X,
MYRIP:NM_015460:exon8:c.G7
81T:p.G261X,
OR5K3:NM_001005516:exon1:c
.G439T:p.G147X,
SRD5A3:NM_024592:exon2:c.G
301T:p.G101X,
MYO10:NM_012334:exon39:c.C
5500T:p.R1834X,
PCDHB11:NM_018931:exon1:c.
G610T:p.E204X,
GSTA5:NM_153699:exon7:c.C5
95T:p.Q199X,
SYNE1:NM_033071:exon141:c.
C25512A:p.C8504X,SYNE1:NM
_182961:exon141:c.C25656A:p.
C8552X,
FAM208B:NM_017782:exon11:
c.C1078T:p.Q360X,
SLC6A15:NM_018057:exon3:c.
C379T:p.R127X,SLC6A15:NM_
182767:exon3:c.C379T:p.R127X
,SLC6A15:NM_001146335:exon
2:c.C58T:p.R20X,
MAPKAPK5:NM_139078:exon1
4:c.G1411T:p.E471X,MAPKAP
K5:NM_003668:exon14:c.G1405
T:p.E469X,
ESD:NM_001984:exon4:c.G150
A:p.W50X,
ZFYVE1:NM_021260:exon2:c.C
54A:p.C18X,
NOD2:NM_022162:exon4:c.C15
04T:p.Q502X,
SLC2A4:NM_001042:exon2:c.C
109T:p.Q37X,
RPL23A:NM_000984:exon3:c.A
307T:p.K103X,
LRRC37A3:NM_199340:exon11
:c.G3568T:p.E1190X,
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stopgain

chr17

78172484

C

T

stopgain

chr19

45575836

G

A

stopgain

chr20

10279932

C

T

stopgain

chr22

31331037

G

A

CARD14:NM_052819:exon10:c.
C1234T:p.R412X,
ZNF296:NM_145288:exon3:c.C
451T:p.R151X,
SNAP25:NM_130811:exon7:c.C
424T:p.R142X,SNAP25:NM_00
3081:exon7:c.C424T:p.R142X,
MORC2:NM_014941:exon20:c.
C1738T:p.R580X,

(a) Noval stopgain and stoploss SNPs in SW48
function

chromosome

position

reference

SNP

Gene information

stopgain

chr1

15888764

C

T

stopgain

chr1

85561701

C

T

stopgain

chr1

108742652

C

A

stopgain

chr1

151751716

T

A

stopgain

chr1

157516869

C

T

stopgain

chr2

54885067

C

T

stopgain

chr2

149543893

A

T

stopgain

chr2

198949979

C

T

stopgain

chr2

236945333

C

T

stopgain

chr3

98304503

C

T

stopgain

chr3

113374426

C

A

stopgain

chr5

36036015

G

A

stopgain

chr5

98129453

T

A

stopgain

chr5

112901596

C

T

stopgain

chr6

152476161

G

A

DNAJC16:NM_015291:exon9:
c.C1282T:p.Q428X,
WDR63:NM_145172:exon11:c
.C1261T:p.Q421X,
SLC25A24:NM_013386:exon1
:c.G109T:p.G37X,
TDRKH:NM_006862:exon5:c.
A424T:p.R142X,TDRKH:NM_
001083963:exon5:c.A424T:p.R
142X,TDRKH:NM_001083965
:exon5:c.A424T:p.R142X,
FCRL5:NM_031281:exon3:c.G
171A:p.W57X,FCRL5:NM_00
1195388:exon3:c.G171A:p.W5
7X,
SPTBN1:NM_178313:exon29:
c.C6088T:p.R2030X,SPTBN1:
NM_003128:exon30:c.C6127T:
p.R2043X,
EPC2:NM_015630:exon14:c.A
2371T:p.R791X,
PLCL1:NM_006226:exon2:c.C
1738T:p.R580X,
AGAP1:NM_001037131:exon1
4:c.C1774T:p.Q592X,AGAP1:
NM_014914:exon13:c.C1615T:
p.Q539X,
CPOX:NM_000097:exon5:c.G
954A:p.W318X,
KIAA2018:NM_001009899:ex
on7:c.G6103T:p.G2035X,
UGT3A2:NM_001168316:exo
n6:c.C1255T:p.Q419X,UGT3A
2:NM_174914:exon7:c.C1357T
:p.Q453X,
RGMB:NM_001012761:exon5:
c.T1433A:p.L478X,
YTHDC2:NM_022828:exon21:
c.C2722T:p.Q908X,
SYNE1:NM_033071:exon132:
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c.C23782T:p.R7928X,SYNE1:
NM_182961:exon133:c.C2399
5T:p.R7999X,
AK8:NM_152572:exon13:c.C1
282T:p.Q428X,
ROBO4:NM_019055:exon6:c.
C991T:p.R331X,
WIBG:NM_001143853:exon3:
c.G352T:p.E118X,WIBG:NM_
032345:exon3:c.G355T:p.E119
X,
B2M:NM_004048:exon1:c.C64
T:p.Q22X,
POLG:NM_001126131:exon19
:c.C3067T:p.Q1023X,POLG:N
M_002693:exon19:c.C3067T:p
.Q1023X,
ZNF688:NM_145271:exon3:c.
G346T:p.E116X,ZNF688:NM_
001024683:exon3:c.G304T:p.E
102X,
DNAH2:NM_020877:exon24:c
.C3985T:p.Q1329X,
UBA2:NM_005499:exon9:c.G
819A:p.W273X,
ACTN4:NM_004924:exon21:c.
C2659T:p.Q887X,
PIH1D1:NM_017916:exon8:c.
C751T:p.Q251X,
CENPI:NM_006733:exon21:c.
C2256A:p.C752X,
DOCK11:NM_144658:exon34:
c.G3730T:p.E1244X,
MYBPH:NM_004997:exon10:
c.A1434G:p.X478W,
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